Agomab’s ALK5 inhibitor hits target in phase 2 Crohn’s disease trial
Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of fibrostenosing Crohn’s disease.
Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of fibrostenosing Crohn’s disease.
